Medical lens company STAAR Surgical (NASDAQ: STAA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 111% year on year to $93.54 million. Its non-GAAP profit of $0.25 per share was 9.7% above analysts’ consensus estimates.
Is now the time to buy STAA? Find out in our full research report (it’s free for active Edge members).
STAAR Surgical (STAA) Q2 CY2026 Highlights:
- Revenue: $93.54 million vs analyst estimates of $90.51 million (111% year-on-year growth, 3.3% beat)
- Adjusted EPS: $0.25 vs analyst estimates of $0.23 (9.7% beat)
- Adjusted EBITDA: $20 million vs analyst estimates of $17.64 million (21.4% margin, 13.4% beat)
- Operating Margin: 10.8%, up from -67.6% in the same quarter last year
- Market Capitalization: $1.27 billion
StockStory’s Take
STAAR Surgical’s second quarter results surpassed Wall Street’s expectations for both revenue and adjusted earnings, but the market reacted negatively, likely reflecting investor caution about the sustainability of recent growth. Management attributed the strong quarter to increased adoption of EVO Plus in China, ongoing market share gains from laser-based competitors, and consistent double-digit growth outside China, especially in the U.S. and EMEA. CEO Warren Foust emphasized that the company’s performance was supported by demand-driven growth in China, rather than inventory build, and highlighted the successful rollout of the new ERP system as a contributor to operational improvements.
Looking ahead, management sees continued opportunity in expanding its lens-based refractive platform, with a focus on broadening the product portfolio beyond EVO. The company is investing in innovation, including new product development and the hiring of a chief technology officer to lead R&D initiatives. Foust noted that as supply constraints ease, STAAR Surgical plans to meet accelerating global demand for its products. However, the team acknowledged uneven conditions in the overall refractive market and continued headwinds from tariffs and currency fluctuations, particularly in Asia. Foust stated, "Our focus remains on revenue growth, expanding profitability, and advancing innovation."
Key Insights from Management’s Remarks
Management cited three main drivers behind the second quarter’s performance: strong EVO Plus uptake in China, profitability improvements across regions, and progress in technology and operational infrastructure.
- China EVO Plus momentum: Expansion of EVO Plus in China drove significant market share gains, with management noting the product exceeded initial expectations and now accounts for roughly a third of Chinese unit sales.
- Global market share gains: The company highlighted that lens-based refractive procedures are outperforming laser-based procedures worldwide, with patients and surgeons increasingly preferring EVO due to its reversibility and non-corneal approach.
- U.S. and EMEA growth: STAAR Surgical saw another quarter of double-digit growth in the U.S. and EMEA (excluding the Middle East), driven by increased surgeon confidence and patient demand for lens alternatives to LASIK.
- ERP system rollout completed: The new enterprise resource planning (ERP) system went live, providing improved business visibility and scalability. Management described the system as a foundation for future AI-enabled capabilities and operational efficiency.
- Profitability and cash flow milestone: The company achieved a return to profitability and free cash flow, supported by margin expansion and disciplined cost control. CFO Deborah Andrews said operating expenses were managed closely, with restructuring and ERP consulting costs expected to decline going forward.
Drivers of Future Performance
Management’s outlook is shaped by ongoing demand in China, further EVO Plus adoption, and expanded R&D initiatives, while also acknowledging macro headwinds and the need to scale supply.
- China demand and seasonality: Continued adoption of EVO Plus is expected to drive growth in China, particularly in the first half of the year due to seasonality, though management warned that Q3 and Q4 will be sequentially softer compared to Q2.
- Supply chain and manufacturing shift: The company aims to manufacture all Chinese-destined product in Switzerland by year-end to reduce tariff-related margin pressure, which should support profitability if successfully executed.
- Product innovation and platform strategy: STAAR Surgical plans to diversify its product portfolio, moving beyond a single-product focus with new lens technologies and first-in-human clinical studies expected soon. The hiring of a chief technology officer reflects this strategic priority, with management positioning the company for long-term growth in the broader refractive market.
Catalysts in Upcoming Quarters
Over the coming quarters, our team will be watching (1) whether EVO Plus supply can meet demand in China and further drive share gains, (2) the successful migration of manufacturing to Switzerland to lessen tariff impacts on margins, and (3) the rollout of new R&D initiatives and clinical studies for next-generation lens products. Progress in U.S. adoption and the effectiveness of operational investments will also be important markers.
STAAR Surgical currently trades at $24.76, down from $25.41 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
